Efficacy and Safety of Once-Weekly Semaglutide Versus Daily Canagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes (SUSTAIN 8): A Double-Blind, Phase 3b, Randomised Controlled Trial

The Lancet Diabetes and Endocrinology - Netherlands
doi 10.1016/s2213-8587(19)30311-0

Related search